Comment on "Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration"

Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3733-3734. doi: 10.1007/s00417-024-06515-9. Epub 2024 Jun 7.

E Stradiotto^{1

2}, G Ottonelli^{3

4}, M R Romano³, C La Spina⁴

¹ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 Pieve, Emanuele, 20072, Milan, Italy. elisa.stradiotto@humanitas.it.
² Department of Ophthalmology, Eye Unit Humanitas Gradenigo, Corso Regina Margherita, 8/10, 10153, Turin, Italy. elisa.stradiotto@humanitas.it.
³ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 Pieve, Emanuele, 20072, Milan, Italy.
⁴ Department of Ophthalmology, Eye Unit Humanitas Gradenigo, Corso Regina Margherita, 8/10, 10153, Turin, Italy.

No abstract available

Keywords: Age-related Macular Degeneration; Brolucizumab; Faricimab; Intravitreal injection.

Publication types